Local Anesthetic for Plateau Fractures
Launched by UNIVERSITY OF WASHINGTON · Jun 19, 2024
Trial Information
Current as of September 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a local anesthetic called bupivacaine for people who have a specific type of broken leg called a tibial plateau fracture. The goal is to see if giving an injection of this anesthetic at the end of surgery can help reduce pain and possibly shorten the time patients need to stay in the hospital after their surgery.
To be eligible for this trial, participants must be at least 18 years old and have a tibial plateau fracture that requires surgery to fix. However, people who are allergic to bupivacaine or who have had prolonged use of an external fixator (a type of temporary support for broken bones) will not be able to participate. If you join the trial, you can expect to receive the standard care for your fracture, along with the possibility of the pain-relieving injection after surgery. The trial is currently not recruiting participants, but it aims to help doctors find better ways to manage pain for patients with similar injuries in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>=18 year ,
- • tibial plateau fracture undergoing Open Reduction and fixation"
- Exclusion:
- • allergy to bupivacaine
- • Prolonged external fixator use
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jonah Hebert-Davies
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported